<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00926835</url>
  </required_header>
  <id_info>
    <org_study_id>MIHWAF-CRCD-K-01</org_study_id>
    <nct_id>NCT00926835</nct_id>
  </id_info>
  <brief_title>Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients</brief_title>
  <official_title>A Study to Investigate the Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder (MDD) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health &amp; Welfare, Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ministry of Health &amp; Welfare, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to investigate the effectiveness of antidepressants on
      the treatments for non-psychotic major depressive disorder (MDD) in Korea. The study divides
      MDD patients into 3 level groups according to their past histories to treatments and compares
      the effectiveness of various treatment regimens at each level.

      The treatment level groups are: 1) patients who have never been treated with appropriate
      medications for their current depressive symptoms before, 2) who received an appropriate SSRI
      (Selective Serotonin Reuptake Inhibitor) once but did not respond to it, 3) who received two
      types of SSRI antidepressant treatments without much effects in reducing their depressive
      symptoms.

      The first level group will be treated with a single SSRI antidepressant treatment. The second
      and third level groups, who received SSRI treatment before, will be treated with alternative
      SSRI antidepressants (switching), combined multiple SSRI treatments (antidepressant
      combination), or SSRI treatments combined with mood stabilizer or anti-psychotics
      (augmentation). This study does not use placebos. Patients will visit 5 times for 6 weeks at
      each level for treatments. Patients will be evaluated for the severity of depressive
      symptoms, functional level, and side effects at each visit. Afterwards, the investigations
      will combine to monitor the patients depressive symptoms in every 3 months for the next 24
      months. 18 nationwide university hospitals will participate in this study. This multi-site,
      prospective, and naturalistic study for patients with depression in Korea is a main project
      of 'Clinical Research Center for Depression' funded by the Ministry for Health, Welfare, and
      Family Affairs (MIHWAF) in Korea for a highly-qualified research achievement.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be classified into 3 levels by their past therapeutic histories:

      Level 1: Patients who do not receive an appropriate treatment for their current major
      depressive episode.

      Level 2: Patients who never showed a satisfactory response to an adequate dosage of
      Paroxetine during a sufficient period of their current major depressive episode.

      Level 3: Patients without a satisfactory response to two or more antidepressants including
      one of Paroxetine or Escitalopram for a sufficient period.

      A satisfactory response means baseline HAM-D17 score was reduced over 50% or HAM-D17 score 10
      or below and a sufficient period means 6 weeks.

      Patients will be randomly assigned to the following treatment groups. Patients in level 1
      will be randomly assigned to treatment groups among Paroxetine monotherapy, Escitalopram
      monotherapy, or Venlafaxine monotherapy.

      Patients in level 2 will be enrolled who were medicated Paroxetine monotherapy in level 1 and
      assigned to one of the following 4 groups; Escitalopram monotherapy, Venlafaxine monotherapy,
      Paroxetine combined with Venlafaxine, or Paroxetine augmented with Lithium.

      Patients in level 3 will be randomly assigned to one of the following 4 groups: 1) Either
      Paroxetine combined with Lamotrigine or Paroxetine combined with Bupropion if they resist two
      antidepressants including Paroxetine. 2) Either Escitalopram combined with Mirtazapine or
      Escitalopram combined with Aripiprazole if they resist two antidepressants including
      Escitalopram. 3) Patients who does not respond to both Paroxetine and Escitalopram will be
      randomly assigned to either 1) or 2).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to patient recruitment difficulties
  </why_stopped>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale</measure>
    <time_frame>6 week</time_frame>
  </primary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">692</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Paroxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paroxetine monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Escitalopram monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venlafaxine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Venlafaxine monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Paroxetine+Bupropion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Paroxetine+Lamotrigine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Paroxetine+Lithium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>escitalopram+mirtazapine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Escitalopram+Aripiprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Paroxetine + Venlafaxine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paroxetine</intervention_name>
    <description>6 weeks, 20-50mg/day</description>
    <arm_group_label>Paroxetine</arm_group_label>
    <other_name>Seroxat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>10-20mg/day for 6 weeks</description>
    <arm_group_label>Escitalopram</arm_group_label>
    <other_name>lexapro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine XR</intervention_name>
    <description>Venlafaxine 75-225mg/day for 6 weeks</description>
    <arm_group_label>Venlafaxine</arm_group_label>
    <other_name>Efexor XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine+Bupropion</intervention_name>
    <description>paroxetine 20-50mg/day + bupropion 150-400mg/day for 6 weeks</description>
    <arm_group_label>Paroxetine+Bupropion</arm_group_label>
    <other_name>Seroxat, wellbutrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine+Lamotrigine</intervention_name>
    <description>Paroxetine 20-50mg/day + lamotrigine 100-400mg/day for 6 weeks</description>
    <arm_group_label>Paroxetine+Lamotrigine</arm_group_label>
    <other_name>seroxat, lamictal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine+Lithium</intervention_name>
    <description>Paroxetine 20-50mg/day + lithium 0.5-1.2 mEq/L</description>
    <arm_group_label>Paroxetine+Lithium</arm_group_label>
    <other_name>seroxat, lithan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram+Mirtazapine</intervention_name>
    <description>escitalopram 10-20mg/day + mirtazapine 15-45mg/day for 6 weeks</description>
    <arm_group_label>escitalopram+mirtazapine</arm_group_label>
    <other_name>lexapro, remeron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram+Aripiprazole</intervention_name>
    <description>escitalopram 10-20mg/day + aripiprazole 5-15mg/day for 6 weeks</description>
    <arm_group_label>Escitalopram+Aripiprazole</arm_group_label>
    <other_name>lexapro, abilify</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paroxetine + Venlafaxine XR</intervention_name>
    <description>Paroxetine 20-50mg/day + Venlafaxine 75-225mg/day for 6 weeks</description>
    <arm_group_label>Paroxetine + Venlafaxine</arm_group_label>
    <other_name>seroxat, efexor XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of non-psychotic Major depressive disorder

          -  HAMD-17 score 14 or greater

          -  Age of 18 or greater and 65 or less

        Exclusion Criteria:

          -  patients with current or past history of diagnosis of bipolar disorder, schizophrenia,
             schizoaffective disorder, or psychotic disorder NOS

          -  patients with current psychotic features, eating disorders or obsessive-compulsive
             disorder

          -  patients with neurological disorder

          -  patients with medical condition that could interfere with everyday life activities

          -  pregnant or lactating women,

          -  patients with current other DSM-IV TR Axis I diagnosis other than MDD which needs
             inpatient care

          -  patients who treated with ECT for current depressive episode

          -  insufficient information of past treatment for current depressive episode

          -  patients who posed a serious suicidal risk.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae-Youn Jun, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical research center for depression</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical research center for depression</name>
      <address>
        <city>Seoul</city>
        <zip>150713</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2009</study_first_submitted>
  <study_first_submitted_qc>June 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2009</study_first_posted>
  <last_update_submitted>September 1, 2015</last_update_submitted>
  <last_update_submitted_qc>September 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Jun Tae-Youn</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Lithium Carbonate</mesh_term>
    <mesh_term>Paroxetine</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
    <mesh_term>Mirtazapine</mesh_term>
    <mesh_term>Mianserin</mesh_term>
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
    <mesh_term>Aripiprazole</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

